
Weightlifting made Casey Johnston stronger — in muscle and mind
Social Sharing
After years of following diets and running a bunch of half-marathons, journalist and editor Casey Johnston finally hit her goal weight of 138 pounds at age 26.
But after all that, she didn't find the happiness or self-confidence she was promised. Instead, she felt deeply hopeless, running on empty.
"I realized I was hoping for this moment when everything would feel like it clicked and I would not have to be trying so hard," she said on Bookends with Mattea Roach. "[Where] it didn't take so much effort and so much of my mental energy and physical energy in order to just be comfortable in my body."
"But I found that the longer it went on, the more kind of maintenance it seemed to take, the more the more energy and the more attention."
That's when she remembered a Reddit post about weightlifting — and decided to try it — despite everything telling her that it wouldn't get her where she wanted to go.
Now, years later, she writes about the unexpected healing she gained from weight training in her book A Physical Education.
She joined Roach to discuss her journey to finding joy and acceptance in her body and, at the same time, her spirit.
Mattea Roach: Where did the priority of optimizing your body come from for you, do you think?
Casey Johnston: I tried to take a really honest inventory over the course of writing this book of how my thoughts have been shaped over and my view of myself and working out and food over the course of my life.
I mean, there's cultural forces. There's the stuff we read in magazines. The ubiquitous presence of celebrity doctors who present themselves as having all of these quick, easy answers. There were, at the time, women's magazines that had so much to say about the best fruits for weight loss etcetera, but then there was also my own family background.
My father was an alcoholic. We all struggled with that. My mother had her own traumatic background and it really created this dynamic of, when I was a child, that I always had to be on my toes. It was very performance-oriented in a way that I felt like I had to maximize my own performance to make everything as okay, as safe as possible for myself. That's not something that kids should have to go through, but it sort of permeated outward into how I saw my place in the world, which was that my role, my job as a person was to be responsive to all of these instructions that I was getting, that I had to produce my own safety and my own place in the world through this hard work of of following all these instructions that people were giving in order for acceptance.
So you're in this spot where running, cardio, dieting is not working for you. You come across this Reddit post that clearly made an impact on you about a woman with a different approach to fitness: weightlifting. What sorts of things did she reveal to you about dieting and strength? What spoke to you in her story?
When I saw this post I was completely blown away by it because I had always been told that lifting weights will make you bulky, that if you just sort of want to lose weight, that lifting weights is sort of a bridge too far unless you want to be some mega-strength person. So I was fascinated when I came across this post.
A lot of times when you see before and after photos, they're about the exaggerated transformation. I was used to seeing infomercials for weight loss products where people had really changed a lot. What was fascinating to me was actually that her body hadn't changed that much. It had changed in minor ways. And I liked the aesthetic changes, but I was like, I've been warned up and down how much lifting weights would do everything you didn't want.
She was here doing all of these things that I had been told not to do and she was not only fine, but she was so happy and having a great time.
But after looking at her pictures, I was like, she's not that different. And not only that — in her description of what she was doing, she was only working out three times a week. She was only doing five reps at a time of three movements for a few sets and then she was done. So that was taking her 30 minutes. She was eating way more than I was at that time.
She was here doing all of these things that I had been told not to do and she was not only fine, but she was so happy and having a great time.
Was there ever a point in your lifting journey where you felt concerned that you were pushing yourself just to push yourself like you had been in previous workout routines?
What I keep coming back to is that there are so many mechanisms that are inherently about building yourself up, about protecting yourself, and building a relationship with yourself, which really was the most important part of it to me.
There's this just atomic unit of lifting that I hadn't experienced in any other physical activity though, you could apply it, just no one does. But it was more built into lifting.
You would do a rep or do a set and ask yourself, 'How did that feel?' What was my experience of that? Was the weight too heavy? Was it too light? How did my forearm feel? Do I feel like I'm feeling this in the right muscles?
I was able to understand how I was feeling about so many other things in a way that I had never done before. - Casey Johnston
And a lot of these questions you don't know the answer at first and that is okay, but you're encouraged in this practice of inquiry of yourself and experience of something and that, to me, was so significant because pursuant to my personal background and pursuant to how a lot of us, but women especially, are treated in cultures to discourage inquiry of your experience. To push down whatever it is that you're feeling because someone else's feelings are more important, because someone else has greater needs than you. And that's not to say that you are the most important person in any room, but that this is an experience of yourself that radiates outward.
The experience of asking myself how I felt and lifting encouraged me to develop that practice more outside in the world and I was able to understand how I was feeling about so many other things in a way that I had never done before.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
29 minutes ago
- Globe and Mail
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV in newborns and infants born during or entering their first RSV season. The drug will be marketed under the brand name Enflonsia. The FDA's decision came a day ahead of the previously announced target date of June 10, 2025. The approval is based on data from the pivotal phase IIb/III CLEVER study, which showed that treatment with a single dose of Enflonsia significantly reduced the incidence of RSV disease and hospitalization in healthy preterm and full-term infants. Merck plans to launch Enflonsia in the United States ahead of the upcoming 2025-26 RSV season and expects ordering for the shots to start next month. Per a Reuters article, Merck will price the antibody at $556 per dose. Merck's Stock Performance Year to date, Merck's shares have lost 20% compared with the industry 's 1% decline. Other RSV Antibodies/Vaccines Available in the Market Once commercially launched, Merck's Enflonsia will face stiff competition from AstraZeneca AZN / Sanofi 's SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023. This AstraZeneca-Sanofi antibody achieved blockbuster status in its first full-year sales in 2024. Coincidentally, on the same day Enflonsia received approval, Sanofi revealed an aggressive effort to increase the supply of the AstraZeneca-partnered Beyfortus, including a plan to start shipping the antibody early in the third quarter of 2025. While there are multiple vaccines approved for preventing RSV in the United States, the only one approved for immunizing infants is Pfizer 's PFE Abrysvo. Unlike Beyfortus and Enflonsia, which can be administered directly, the Pfizer vaccine protects infants through maternal immunization. Most of the marketed RSV vaccines, including Pfizer's, are approved for use in older adults aged 60 years and above. MRK's Cholesterol Drug Meets Goal in Two Late-Stage Studies In a separate press release, Merck announced topline data from two phase III studies, CORALreef HeFH and CORALreef AddOn, which evaluated their investigational oral PCSK9 inhibitor, enlicitide decanoate, in adults with hyperlipidemia who had been previously treated with a statin. Both studies met their primary and key secondary endpoints, showing statistically significant and clinically meaningful greater reductions in low-density lipoprotein cholesterol (LDL-C) after treatment with enlicitide. While the CORALreef HeFH evaluated the drug against a placebo, the CORALreef AddOn assessed the drug against other oral non-statin therapies. MRK's Zacks Rank Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report This article originally published on Zacks Investment Research (

National Post
33 minutes ago
- National Post
EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development
Article content NEW YORK — EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advancements in digital transformation within the life sciences industry. This engagement combines EDETEK's deep domain expertise and established platforms and services with Capgemini's advanced AI and engineering capabilities, to enable EDETEK to deliver innovative solutions aimed at optimizing clinical development, improving operational efficiency, and accelerating the time-to-market for new therapies. Article content A shared vision for the future of clinical R&D Article content Article content By integrating advanced digital and data capabilities—including generative AI—across all phases of clinical trials, the project will support new efficiencies for pharmaceutical companies, including: Article content Dramatically reduce time-to-market for new therapies. Enablement of self-learning, insight-driven trials for faster, more proactive decision-making. Streamlined data management and trial workflows, enhancing efficiency and precision. Significant cost reductions and boosted drug pipeline value. Article content 'Working with Capgemini signifies our continuing efforts to expand our global capabilities towards delivering more effective and faster clinical development,' Article content said Dr. Shakthi Kumar, Chief Strategy & Business Officer at EDETEK. Article content 'By bringing together our AI-driven platforms with Capgemini's leading capabilities in life science and technology, we will empower life science organizations to conduct smarter, faster, and more predictive clinical trials—ultimately improving patient outcomes at scale.' Article content Bringing innovation to clinical development at scale Article content The engagement combines EDETEK's proven technology with Capgemini's global network and deep domain knowledge to scale AI-powered clinical innovation across the pharmaceutical industry. Together, this will help make intelligent, agile, and data-driven clinical trials accessible to more life sciences organizations worldwide. In addition, Capgemini will leverage its robust engineering capabilities to help scale EDETEK's platforms globally and enable continued leadership in reliability, innovation, and performance. Article content 'Our deep expertise in next-gen clinical development methodologies and advanced AI will expand EDETEK's R&D cloud and eClinical platform, helping its clients to unlock new levels of agility, insight, and efficiency,' Article content said Thorsten Rall, Global Industry Head, Life Sciences at Capgemini. 'Together, we are committed to redefining what's possible for the industry—delivering measurable value, accelerating innovation, and shaping the future of healthcare through smarter, more predictive clinical trials.' Article content About EDETEK, Inc. Article content Founded in 2009, EDETEK delivers high-quality AI-powered platforms and clinical services to over one hundred biopharma clients worldwide. With a presence across four continents, EDETEK is redefining the future of clinical development through intelligent technology. Article content For more information about EDETEK, please visit About Capgemini Capgemini is a global business and technology transformation partner, helping organizations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fueled by its market leading capabilities in AI, generative AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2024 global revenues of €22.1 billion. Article content Article content Article content Contacts Article content Capgemini press contact: Article content Article content Julia Zimmerman Article content Article content Tel.:+1 847-922-7951 Article content Article content EDETEK press contact: Article content Article content Wei Kong Article content Article content Article content Article content


Globe and Mail
an hour ago
- Globe and Mail
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw first-quarter 2025 sales decline nearly 50% year over year to $1.12 billion. Humira had already lost exclusivity in ex-U.S. markets in 2018. Despite the steep decline, ABBV's ex-Humira platform grew more than 21% year over year (on a reported basis) in the first quarter of 2025, driven by its newer immunology drugs, Skyrizi and Rinvoq. The company successfully launched Skyrizi and Rinvoq across Humira's major indications and a distinct new indication, atopic dermatitis. Both drugs showed strong performance across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions: ulcerative colitis (UC) and Crohn's disease (CD). Strong immunology-market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs' future growth. On the back of this continued momentum, AbbVie raised its previously issued guidance by around $900 million and now expects to record $24.7 billion from the combined sales of both drugs this year. Our model estimates the combined sales figure to be around $24.85 billion. ABBV's Competition in the Immunology Space The targeted market is highly competitive. A key player in this area is Johnson & Johnson JNJ, which already markets blockbuster medications, Stelara and Tremfya. Both of these J&J drugs are approved across multiple immunology indications, including UC and CD indications. Since Stelara lost U.S. LoE earlier this year, J&J has shifted focus to Tremfya to maintain its foothold in the immunology space. Another pharma giant expanding its presence in immunology is Eli Lilly LLY, following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked Lilly's first immunology drug approved for a type of IBD in the United States and plays a key role in building out its immunology portfolio. This Lilly drug received FDA approval for the CD indication in January. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.48 times forward earnings, a tad lower than its industry's average of 15.12. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk but is priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.38. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has declined from $12.30 per share to $12.28, while that for 2026 has increased from $13.97 to $14.05 over the past 60 days. AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report